Aims/hypothesis Since protein ingestion is known to stimulate the secretion of glucagon-like peptide-1 (GLP-1), we hypothesised that enhancing GLP-1 secretion to harness its insulinotropic/beta cell-stimulating activity with whey protein pre-load may have beneficial glucose-lowering effects in type 2 diabetes. Methods In a randomised, open-label crossover clinical trial, we studied 15 individuals with well-controlled type 2 diabetes who were not taking any medications except for sulfonylurea or metformin. These participants consumed, on two separate days, 50 g whey in 250 ml water or placebo (250 ml water) followed by a standardised high-glycaemic-index breakfast in a hospital setting. Participants were randomised using a coin flip. The primary endpoints of the study were plasma concentrations of glucose, intact GLP-1 and insulin during the 30 min following meal ingestion. Results In each group, 15 patients were analysed. The results showed that over the whole 180 min post-meal period, glucose levels were reduced by 28% after whey pre-load with a uniform reduction during both early and late phases. Insulin and C-peptide responses were both significantly higher (by 105% and 43%, respectively) with whey pre-load. Notably, the early insulin response was 96% higher after whey. Similarly, both total GLP-1 (tGLP-1) and intact GLP-1 (iGLP-1) levels were significantly higher (by 141% and 298%, respectively) with whey pre-load. Dipeptidyl peptidase 4 plasma activity did not display any significant difference after breakfast between the groups. Conclusions/interpretation In summary, consumption of whey protein shortly before a high-glycaemic-index breakfast increased the early prandial and late insulin secretion, augmented tGLP-1 and iGLP-1 responses and reduced postprandial glycaemia in type 2 diabetic patients. Whey protein may therefore represent a novel approach for enhancing glucoselowering strategies in type 2 diabetes. Trial registration ClinicalTrials.gov NCT01571622 Funding The Israeli Ministry of Health and Milk Council funded the research.
Introduction
One of the earliest changes in the development of type 2 diabetes is the loss of early postprandial insulin response, a change which contributes to postprandial hyperglycaemia. Therefore, targeting the early postprandial insulin response is an important glucose-lowering strategy in treating type 2 diabetes [1] . One such potential approach is to augment the beta cell response to glucose by a primary stimulus, as has been observed after sequential OGTTs and with IVGTTs or hyperglycaemic clamps [1, 2] . Another approach is to target the incretin hormone glucagon-like peptide-1 (GLP-1), which is an important mediator for the postprandial insulin response [3] . Indeed, it has been shown that incretin-based therapies, such as GLP-1 receptor agonists [3] and inhibitors of GLP-1 inactivating protease, dipeptidyl peptidase 4 (DPP-4) [4] , augment the insulin secretory response to meal ingestion by enhancing mainly the early phase of insulin secretion in type 2 diabetes patients. Whether combining these two approaches by using increased GLP-1 secretion as a primary stimulus to a subsequent meal ingestion may further improve insulin secretion is not known.
In this study, we report that such an approach with a primary stimulus is indeed achievable by using whey protein, which accounts for 20% of whole-milk protein and is known to stimulate both incretin hormone secretion and insulin secretion [5] . The approach was to serve a pre-meal load of whey protein followed by a regular meal, to examine this prestimulus on postprandial GLP-1 and insulin secretion. Fig. 1 ). Participants were randomised using a coin flip. Each participant consumed two test meals separated by a washout period of at least 2 weeks. At the first visit, participants were randomised to consume a pre-meal drink with either 50 g [920 kJ (220 kcal)] whey protein concentrate (Beit Haemek Advanced Technologies, Beit Haemek, Israel) dissolved in water or water (placebo). A fasting blood sample (t=−30 min) was taken and the pre-meal drinks were served. Blood samples were taken at t=0 min and, immediately after, participants were served a high-glycaemic-index 1,477 kJ (353 kcal) breakfast. Thereafter, blood samples were drawn at t=15, 30, 60, 90, 120, 150, 180 min. Glucose was assessed using an analyser, insulin and C-peptide were measured by electrochemiluminescence immunoassay and total GLP-1 (tGLP-1) and intact GLP-1 (iGLP-1) were quantified by ELISA. DPP-4 activity was assessed as previously described [5] . On the second visit, each participant was crossed over to the opposite pre-meal drink.
Methods

Study population
Power calculation and statistical analyses The primary endpoints of the study were the AUCs for plasma concentrations of glucose, intact GLP-1 and insulin during the 30 min following meal ingestion. Secondary endpoints were the 30 min AUC for concentrations of C-peptide, total GLP-1 and DPP-4. Exploratory analysis also included AUCs for other time intervals. In this study, we examined 15 participants, based on the known variation in AUC for intact GLP-1 and insulin and assuming a 30% difference by the pre-stimulus and desiring to detect this difference with 80% probability; this resulted in the requirement of 15 participants and to allow for discontinuation 19 participants were recruited. The results are expressed as mean ± SEM. For time series, a two-way ANOVA was performed and a least-significant difference t test post hoc analysis was used for comparison between the groups at each time point. For the comparison of fasting with postprandial time points within a group, Dunnet's post hoc test was performed. Student's t test was used for comparing AUCs at different time intervals. In addition, a multivariate ANOVA for repeated measurements was performed, assessing between-and within-subject effects for diet and time.
Results
Glucose, insulin and C-peptide Fasting glucose, insulin and C-peptide levels did not differ significantly between the two test days or the groups (Fig. 1) . In the early interval AUC 0-30 min , plasma glucose excursions were significantly lower in the whey pre-load group (Fig. 1a, Table 1 ). Similarly, plasma glucose excursions were significantly lower at the late interval AUC 60-120 min , and during the complete post-meal period (0-180 min), after whey pre-load compared with placebo (Fig. 1a, Table 1 ).
Whey protein significantly increased the postprandial early insulin release. Plasma insulin levels at the first 30 min were higher and increased more rapidly after whey pre-load (Fig. 1b, Table 1 ). Over the late interval, AUC 60-120 min , and during the complete post-meal period (0-180 min), plasma insulin levels were also significantly higher after whey preload than after placebo (Fig. 1b, Table 1 ). After meal ingestion, C-peptide levels mirrored those of insulin, with a more rapid and higher increase after whey pre-load (Fig. 1c, Table 1 ).
GLP-1 levels and DPP4 activity Higher incremental AUC iGLP-1 and AUC tGLP-1 were observed during all intervals after whey pre-load ( Table 1 ). The peak levels of iGLP-1 and tGLP-1 were higher with whey pre-load. Consequently, during the early interval, whey protein pre-load elicited higher AUC 0-30 min for tGLP-1 and iGLP-1 concentrations (Fig. 1d, e, Table 1 ). Similarly, during the late interval (60-120 min), increased tGLP-1 and iGLP-1 was observed after whey pre-load. The ratio iGLP-1/tGLP-1 was significantly higher throughout the postprandial period after whey pre-load (Fig. 1f) . Positive correlation of insulin to iGLP-1 was marginally significant after placebo, but significant after whey pre-load (Fig. 1g) . DPP4 plasma activity did not display any significant difference after breakfast between the placebo and whey pre-loads (Fig. 1h) .
Discussion
In the present study, we show that a breakfast pre-load of whey protein leads to reduced peak and incremental area for post-meal glucose. This glucose-lowering effect of prestimulation with whey was associated with rapid and significantly enhanced early and late prandial insulin response. Furthermore, the whey pre-load led to significantly increased postprandial iGLP-1 and tGLP-1 responses, predominantly during the early interval (first 30 min). These results are consistent with previous studies indicating that consumption of whey before a meal or with carbohydrates exerts insulinotropic effects and improves post-meal glycaemia in healthy individuals and in those with type 2 diabetes [6] . After the addition of whey, the postprandial glycaemia decreased by 28%, which is a larger reduction than that observed (18%) 180 min after different doses of nateglinide, a rapid-acting non-sulfonylurea insulin secretagogue [7] , and higher than the reduction (12-24%) observed after a standardised meal and sulfonylurea therapy (glipizide and glibenclamide [known as glyburide in the USA and Canada]) [8] . The effects of whey preload, nateglinide and sulfonylureas were not compared in a headto-head fashion. The increase in early insulin secretion with whey vs placebo was~52%, which is comparable with the increase in the early insulin release after breakfast with the addition of 2 mg of repaglinide, a short-acting insulin secretagogue [9] . An important finding was the more rapid and higher early (30 min) iGLP-1 and tGLP-1 response along with enhanced and prolonged rise of both GLP-1 forms at the late interval (60-120 min) of the postprandial response after the whey protein pre-load. It has been suggested that amino acids and bioactive peptides generated during whey protein gastrointestinal digestion directly stimulate L cell activity to secrete GLP-1 and other incretin hormones [10] . The response of iGLP-1 after a meal pre-loaded with whey protein has not been explored previously in individuals with type 2 diabetes. The significantly higher ratio between iGLP-1 and tGLP-1 observed after whey protein may reflect reduced degradation of tGLP-1. An obvious suggestion for an explanation of this would be a lower DPP-4 activity after whey protein. We did not, however, detect any differences in DPP-4 plasma activity between placebo and whey groups. This would suggest that altered inactivation of GLP-1 by whey protein is not executed through changes in plasma DPP-4 activity. Instead, whey protein may serve as an endogenous inhibitor of DPP-4 in the gut, attenuating local GLP-1 degradation after its release from the enteroendocrine cells as previously suggested in animal studies [5] .
A limitation of the study is that we did not examine the detailed mechanisms involved in the effect of the primary stimulus to enhance GLP-1 and insulin secretion, such as the contribution of changes in gastric emptying, meal absorption or the relative contribution of effects on GLP-1 vs insulin secretion, which need to be examined in further mechanistic studies. However, our findings suggest that whey protein may represent a novel approach for enhancing glucose-lowering strategies in type 2 diabetes. Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
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